Ultra-Rare Tumors: Public-Private Partnership Eyed To Boost Drug Development
Executive Summary
US FDA, Foundation for the NIH, and NCI are considering a new PPP aimed at creating a repeatable process for development of drugs to treat ultra-rare cancers where commercial viability is lacking. Stakeholders say industry incentives, IP issues and reimbursement need attention.
You may also be interested in...
EU Filing For Infigratinib Pulled After Commercial Deal Crumbles
BridgeBio’s partner Helsinn terminated its agreement to commercialize infigratinib, which was approved in the US last year for treating the rare bile duct cancer, cholangiocarcinoma.
Keeping Track: US FDA Approval Binge Includes Brexafemme, Wegovy, Ryplazim, Truseltiq, Lybalvi, Tembexa
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Regulatory Flexibility: BrainStorm’s Problematic NurOwn BLA May Be A Bridge Too Far For US FDA
Litany of deficiencies, including product quality shortcomings and a failed Phase III clinical efficacy study, may make it impossible for the agency to exercise the type of flexibility it has with the approval of other treatments for ALS and neurodegenerative diseases.